Chiron trims GAAP guidance

CHIR trimmed its full year GAAP EPS guidance by three pennies to $0.32-$0.42 from $0.35-$0.45. CHIR said the revision reflects a higher than expected amortization expense related to the acquisitions of PathoGenesis; Chiron Behring; Pulmopharm; PowderJect; and Sagres. The expense now is expected to be $0.38, up from the previous estimate of $0.35. ...